Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer Written by Paul Peter Tak on September 11, 2021. Posted in Projects. 2 Comments https://www.biospace.com/article/releases/candel-therapeutics-completes-enrollment-in-phase-3-clinical-trial-of-can-2409-in-combination-with-valacyclovir-for-the-treatment-of-intermediate-high-risk-localized-prostate-cancer/
A glorious moment, knowing that we have secured the proceeds to deliver on our mission to develop better medicines for patients Written by Paul Peter Tak on September 11, 2021. Posted in Projects. Leave a Comment
My message to the Candel Therapeutics team and stakeholders (patients, collaborators, and investors) in 90 sec Written by Paul Peter Tak on September 5, 2021. Posted in Projects. Leave a Comment
